2008
DOI: 10.1007/s00003-008-0323-y
|View full text |Cite
|
Sign up to set email alerts
|

Gene and Cell Therapy in Germany and the EU

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0
1

Year Published

2008
2008
2021
2021

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 12 publications
(10 reference statements)
0
1
0
1
Order By: Relevance
“…The present study used genetically modified NSCs overexpressing GDNF or BDNF neutotrophic factors to examine sciatic nerve regeneration across a long nerve defect. Although genetic manipulation and cell therapy exhibit good effects on curing spinal cord and peripheral nerve injury in animal models, most of them are difficult, risky, or ethically problematic to transfer to the clinic (21). The nonviral transfection was chosen as it reduced the risk of ectotopic and uncontrolled gene expression compared with direct injection.…”
Section: Discussionmentioning
confidence: 99%
“…The present study used genetically modified NSCs overexpressing GDNF or BDNF neutotrophic factors to examine sciatic nerve regeneration across a long nerve defect. Although genetic manipulation and cell therapy exhibit good effects on curing spinal cord and peripheral nerve injury in animal models, most of them are difficult, risky, or ethically problematic to transfer to the clinic (21). The nonviral transfection was chosen as it reduced the risk of ectotopic and uncontrolled gene expression compared with direct injection.…”
Section: Discussionmentioning
confidence: 99%
“…Andererseits überwiegen die Forschungskapazitäten auf den Sektoren der Zell-und Stammzell-Therapie bereits die Studien, die langfristig zur Somatischen Gentherapie in Deutschland betrieben werden. Regenerative Ansätze mit pluripotenten Stamm-Zellen finden sowohl in der Cardiologie, der Hepatologie, der Neurologie als auch beim Knochen-und Stützgewebe den Zugang zu klinischen Studien oder Verträglichkeitsprüfungen (Acikgoez und Bader, 2008;Cichutek, 2008;Yerebakan et al, 2008).…”
unclassified